***IMPORTANT CORRECTION: April 23, 2021 - Several recent news stories incorrectly reported that IES Life Sciences has applied for and is awaiting Emergency Use Approval for its COVID-19 Severity test. Although the company plans to do so in the near future, IES Life Sciences has not yet applied to the FDA for Emergency Use Approval for its Test. *** IES Life Sciences, Inc., (the “Company”) is a Maryland Corporation formed to develop and commercialize, in partnership with the U.S. Food and Drug Administration (“FDA”) via a licensing agreement from the National Institutes of Health (“NIH”), a test kit (assay) capable of detecting and measuring the unique combination of Interferons released by a diseased human cell. Once this “Interferon Expression Signature” (“IFN Signature”) for a particular disease is identified, it can be used to diagnose a disease, determine its severity and create therapies to treat the disease. Repeat testing of the Interferon Expression Signature will allow physicians to adjust the treatment to optimal levels. This test provides significant benefits to the drug development community while also promising to give patients the highest clinical benefit with the fewest side effects at the lowest cost.